Pfizer’s Double Dose Of Good News: Caduet Combo, Spiriva Clear FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Caduet clears FDA for the "simultaneous treatment of high blood pressure and high cholesterol," Pfizer says. The Norvasc and Lipitor combination product could broaden Pfizer’s reach in the cholesterol market.
You may also be interested in...
Pfizer Expects To File 12 "Major" NDAs By The End Of 2006
The company's strategy to weather upcoming patent expirations includes plan to file 20 NDAs over the five-year period ending 2006, U.S. Pharmaceuticals President Pat Kelly tells investors.
Pfizer Expects To File 12 "Major" NDAs By The End Of 2006
The company's strategy to weather upcoming patent expirations includes plan to file 20 NDAs over the five-year period ending 2006, U.S. Pharmaceuticals President Pat Kelly tells investors.
Pfizer Caduet Requires Prior Authorization Under Massachusetts Medicaid
MassHealth is also requiring prior authorization for Amgen’s small molecule chronic kidney agent Sensipar and Lilly’s intramuscular formulation of the antipsychotic Zyprexa.